immune system
• pristane-treated mice show increased spleen:body weight ratio at 6 months post-treatment
|
• mice with pristane-induced lupus nephritis show an increase in the frequency and number of Th17, but not Th1, Treg cells in the spleen
• Th17 cells are prominent in the kidneys of pristine-treated mice
• naive CD4+ T cells grown under Th17 cell differentiation conditions in vitro show generation of a greater frequency of Th17 cells
• however, T cell development in the thymus is not affected in pristane-treated mice compared treated wild-type mice
|
• pristane-treated mice show increased total number of splenocytes at 6 months post-treatment
|
• serum levels of C3 are decreased in pristane-treated mice compared to treated controls
|
• mice show increased pristane (2,6,10,14-tetramethylpentadecane)-induced lupus nephritis, showing more severe and diffuse glomerulonephritis, mesangial hypercellularity and matrix expansion, endocapillary cell proliferation, and glomerular capillary loops with subendothelial immune complex deposition compared to only mild proliferative glomerulonephritis in controls
• however, pristane-treated mice show a similar level of humoral autoimmunity (single-stranded DNA and double-stranded DNA autoantibodies) as controls
• pristane-treated mice injected weekly with an anti-IL-17 antibody from 2 to 6 months show reduced lupus nephritis
|
• pristane-treated mice show more severe and diffuse glomerulonephritis compared to treated controls
|
renal/urinary system
• mice with pristane-induced lupus nephritis show an increased kidney to body weight ratio at 6 months post-induction
|
albuminuria
(
J:287636
)
• albuminuria is increased in pristane-treated mice
• pristane-treated mice injected with an anti-IL-17 antibody show amelioration of albuminuria
|
• glomeruli show greater deposition of IgG, C3, and C1q in the mesangium and capillary loop of mice with pristane-induced lupus nephritis
• the numbers of CD4+ T cells and CD68+ macrophages are increased in the glomeruli of pristane-treated mice
|
• pristane-treated mice show more severe mesangial hypercellularity than treated controls
|
• pristane-treated mice show more severe and diffuse glomerulonephritis compared to treated controls
|
• pristane-treated mice show more severe matrix expansion than treated controls
|
homeostasis/metabolism
• serum levels of C3 are decreased in pristane-treated mice compared to treated controls
|
albuminuria
(
J:287636
)
• albuminuria is increased in pristane-treated mice
• pristane-treated mice injected with an anti-IL-17 antibody show amelioration of albuminuria
|
hematopoietic system
• pristane-treated mice show increased spleen:body weight ratio at 6 months post-treatment
|
• mice with pristane-induced lupus nephritis show an increase in the frequency and number of Th17, but not Th1, Treg cells in the spleen
• Th17 cells are prominent in the kidneys of pristine-treated mice
• naive CD4+ T cells grown under Th17 cell differentiation conditions in vitro show generation of a greater frequency of Th17 cells
• however, T cell development in the thymus is not affected in pristane-treated mice compared treated wild-type mice
|
• pristane-treated mice show increased total number of splenocytes at 6 months post-treatment
|
cellular
• pristane-treated mice show more severe mesangial hypercellularity than treated controls
|
growth/size/body
• mice with pristane-induced lupus nephritis show an increased kidney to body weight ratio at 6 months post-induction
|
• pristane-treated mice show increased spleen:body weight ratio at 6 months post-treatment
|